| I. COMMENCED TRADING IN SEPTEMBER | ||||||||
| Company (Symbol)# | Date Filed | Date Comm. | Shares/ Units (M) | Price | Shares Out (M)@ | Lead, Other Underwriters | Gross (US$M) | Post-Offering Market Cap (M)% |
| INITIAL OFFERINGS | ||||||||
| GNI Ltd. (Japan; TSE:2160)1 | 9/4 | 9/4 | 10S | 90 yen | N/A | N/A | 900 yen ($7.7) | N/A |
| Total: $7.7M | ||||||||
|
Number of IPOs in September: 1 Average value of September IPOs: $7.7 Number of IPOs in 2007: 32 Total raised in IPOs in 2007: $1,570.9M Average value of IPOs in 2007: $49.09M | ||||||||
| FOLLOW-ON OFFERINGS | ||||||||
| Company (Symbol)# | Date Filed | Date Comm. | Shares/ Units (M) | Price | Shares Out (M)@ | Lead, Other Underwriters | Gross (M) | Post-Offering Market Cap (M)% |
| Exelixis Inc. (EXEL)2 | 9/10/07 | 9/13/07 | 7S | $10.30 | 104.3 | Goldman, Sachs & Co. | $72.1 | $1,074.29 |
| InterMune Inc. (ITMN)3 | 9/19/07 | 9/21/07 | 4.525S | $19.50 | 39.2 | Goldman, Sachs & Co. Deutsche Bank (co-lead) CIBC World Markets |
$88.2 | $764.4 |
| Progenics Pharmaceuticals Inc. (PGNX)4 | 9/20/07 | 9/20/07 | 2.6S | $23.15 | N/A | UBS Investment Bank CIBC World Markets Morgan Stanley & Co. |
$57 | N/A |
| Total: $217.3M | ||||||||
|
Number of follow-on offerings in September: 3 Average value of September follow-ons: $72.4M Number of follow-on offerings in 2007: 42 Total raised in follow-ons in 2007: $2,698M Average value of follow-ons in 2007: $64.24M | ||||||||
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange. @ This column reflects the shares outstanding following the offering, when disclosed. % Market capitalization is calculated based on the offering price. Currency conversions are based on exchange rates at the time of the deal. TSE = Tokyo Stock Exchange 1 GNI went public on the Tokyo Stock Exchange. 2 Exelixis' overallotment option: 1.1M shares. 3 Includes InterMune's overallotment option: 525,000 shares 4 Progenics' overallotment option: 390,000 shares. | ||||||||
| II. FILED AND PENDING | ||||||||
| Company (Symbol/Proposed Symbol)#* | Date Filed | Shares/Units (M) | Price Range | Shares Out (M)@ | Lead, Other Underwriters | Value (M) | ||
| INITIAL OFFERINGS | ||||||||
| Anacor Pharmaceuticals Inc. (ANAC) | 8/31/07 | N/A | N/A | N/A | Morgan Stanley & Co. Inc. Cowen & Co. LLC (co-lead) Pacific Growth Equities LLC Needham & Co. LLC |
$57.5 | ||
|
Archemix Corp. (ARCH) |
7/25/07 | N/A | N/A | N/A | Banc of America Securities Bear, Stearns & Co. Inc. Cowen and Co. |
$69 | ||
| ARYx Therapeutics Inc. (ARYX) | 8/31/07 | N/A | N/A | N/A | Morgan Stanley & Co. Inc. CIBC World Markets Corp. Jefferies & Co. Inc. Leerink Swann & Co. Inc. |
$86.25 | ||
| Bioheart Inc. (BHRT)1 | 2/13/07 | 3.575 | $14-$16 | 16.9 | BMO Capital Markets Corp. Janney Montgomery Scott (co-lead) Merriman Curhan Ford & Co. |
$53.6 | ||
| Biolex Inc. (BLEX) | 8/14/07 | N/A | N/A | N/A | Lehman Brothers Inc.Deutsche Bank Securities (co-lead) Leerink Swann & Co. Inc. |
$70 | ||
| Elixir Pharmaceuticals Inc. (ELXR) | 9/24/07 | N/A | N/A | 143.5 | Credit Suisse Securities LLC Pacific Growth Equities Leerink Swann LLC |
$86 | ||
| Genoptix Inc. (GXDX) | 8/1/07 | N/A | N/A | N/A | Lehman Brothers Banc of America Sec. Cowen and Co. |
$86.25 | ||
| Insys Therapeutics Inc. (INRX) | 8/20/07 | N/A | N/A | N/A | Banc of America Securities UBS Investment Bank (co-lead) JMP Securities Natixis Bleichroeder |
$86.25 | ||
| Light Sciences Oncology Inc.(LSON) | 4/21/06 | 5.25S | $14-$16 | 18.5 | Cowen & Co. Wachovia Securities (co-lead) Jefferies & Co. Thomas Weisel Partners |
$78.75 | ||
| MAP Pharmaceuticals Inc. (MAPP) | 6/18/07 | 5S | $14-$16 | 19.3 | Merrill Lynch & Co. Morgan Stanley (co-lead) Deutsche Bank Sec. |
$75 | ||
| Merrion Pharmaceuticals Ltd. (MERR)2 | 4/3/07 | 4S | $10-$12 | 15 | Punk, Ziegel & Co. Goodbody Stockbrokers Stanford Group Co. |
$44 | ||
|
MonoSol Rx Inc. (MSRX) |
5/14/07 | 4S | $16-$18 | N/A | Cowen and Co. CIBC World Markets Susquehanna Financial |
$68 | ||
|
Nanoshere Inc. (NSPH) |
8/13/07 | N/A | N/A | N/A | Credit Suisse Piper Jaffray Leerink Swann & Co. Allen & Co. LLC |
$100 | ||
| NovaBay Pharmaceuticals Inc. (AMEX:NBY; TSX:NBY)3 | 2/15/07 | 5S | $4-$6 | 21.1 | Dundee Securities Desjardins Sec. International Blackmont Capital Dawson James Sec. |
$25 | ||
| Peplin Inc. (PLIN)4 | 8/10/07 | N/A | N/A | N/A | Merrill Lynch & Co. Cowen & Co. LLC Thomas Weisel Partners Leerink Swann & Co. Merrill Lynch International Wilson HTM |
$75 | ||
| Precision Therapeutics Inc. | 8/24/07 | N/A | N/A | N/A | JP Morgan Piper Jaffray (co-lead) JMP Securities |
$80.5 | ||
| Reliant Pharmaceuticals Inc. (NYSE:RRX) | 8/10/07 | N/A | N/A | N/A | Goldman, Sachs & Co. Merrill Lynch & Co. (co-lead) Bank of America Securities Lazard Capital Markets |
$400 | ||
| Talecris Biotheraeutics Holdings Corp. (TLCR) | 7/30/07 | N/A | N/A | N/A | Morgan Stanley Goldman Sachs & Co. J.P. Morgan |
$1B | ||
| Targanta Therapeutics Corp. (TARG) | 5/14/07 | 5.8S | $12-$14 | 21 | Credit Suisse Securities Cowen and Co. Lazard Capital Markets Leerink Swann and Co. |
$75.4 | ||
| FOLLOW-ON OFFERINGS | ||||||||
| Ambrilia Biopharma Inc. (Canada; TSX:AMB) | 9/18/07 | N/A | N/A | N/A | Canaccord Capital Dundee Securities Loewen, Ondaatje, McCutcheon |
$15 | ||
| Bionovo Inc. (BNVI) | 9/24/07 | 11.4S | $3.99 | 77.4 | BMO Capital Markets Canaccord Adams (co-lead) Merriman Curhan Ford & Co. |
$45.5 | ||
| Bioxel Pharma Inc. (Canada; CDNX:BIP)5 | 7/9/07 | N/A | N/A | N/A | Paradigm Capital Laurentian Bank Sec. |
N/A | ||
| Chemokine Therapeutics Corp. (Canada; TSX:CTI; OTC BB: CHKT) | 5/30/07 | N/A | N/A | N/A | GMP Securities | $25 | ||
| Neurobiological Technologies Inc. (NTII) | 8/13/07 | N/A | N/A | N/A | Merriman Curhan Ford | $75 | ||
| Neurochem Inc. (NRMX) | 1/18/07 | N/A | N/A | N/A | N/A | $102 | ||
| WITHDRAWN AND POSTPONED | ||||||||
| Company (Symbol/Proposed Symbol)#* | Date Filed/ Date Pulled | Shares/ Units (M) | Price Range | Shares Out (M)@ | Lead, Other Underwriters | Value (M) | ||
| Adnexus Therapeutics Inc. (ADNX)6 | 8/22/07 9/24/07 |
N/A | N/A | N/A | Lehman Brothers UBS Securities (co-lead) Cowen & Co. Lazard Freres & Co. LLC |
$86 | ||
|
Notes: # Unless otherwise indicated, shares are traded on the Nasdaq exchange; general shelf registration statements are not included until action is taken on the filing. | ||||||||
|
1 Bioheart's overallotment option: 536,250 shares. 2 Merrion plans to list American depositary shares on Nasdaq and ordinary shares in a secondary listing on the Irish Enterprise Exchange, both under the ticker "MERR." 3 NovaBay is seeking a dual listing on the American and Toronto stock exchanges. 4 Peplin Ltd., of Australia, established the U.S. subsidiary to facilitate an IPO. 5 Bioxel filed for a Canadian offering of units consisting of one common share and one-half of a common share purchase warrant. 6 Adnexus pulled its IPO because Bristol-Myers Squibb Co. is acquiring it. | ||||||||
